Yes, and that won't be the end of it. The REAL news will be the CSIRO report which says whether or not Relenza - or any other drug in the BTA arsenal - is useful against colds that kill.
I know that they are too busy in small biotechs to plan good news in research just ahead of reproting seasons and financial years, but I'd be very very surprised if Biota doesn't produce more than the CA review of the literature befor June 30.
So a long term secure biotech can also at the time be an income earning spekky.
BTA Price at posting:
0.0¢ Sentiment: ST Buy Disclosure: Held
